Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy.
OBJECTIVE
To test in mice with experimental autoimmune encephalomyelitis (EAE) a strategy designed to treat patients at risk for axonal degeneration and persistent visual loss from optic neuritis and multiple sclerosis.


METHODS
The authors cloned the human extracellular superoxide dismutase (ECSOD) or catalase (CAT) gene into recombinant adenoassociated virus (AAV). Transgene expression was evaluated by immunochemistry of infected RGC-5 cells and after intravitreal injection of AAV-ECSOD or AAV-CAT, or both, into the right eyes of DBA/1J mice. Control cells and left eyes were inoculated with AAV-GFP. Animals were sensitized for EAE, followed by serial contrast-enhanced MRI for 6 months, and then were euthanatized. The effects of ECSOD and CAT modulation on the EAE optic nerve were gauged by computerized analysis of optic nerve volume, myelin fiber area, axonal cell loss, and retinal ganglion cell (RGC) loss.


RESULTS
Western blot analysis of infected RGC-5 cells revealed that expression of ECSOD increased 15-fold and that of CAT increased 3.5-fold. One month after intraocular injections, transgene expression increased 4-fold for AAV-ECSOD and 3.3-fold for AAV-CAT. Six months after intraocular injections and EAE sensitization, combination therapy with ECSOD and catalase decreased RGC loss by 29%, optic nerve demyelination by 36%, axonal loss by 44%, and cellular infiltration by 34% compared with the contralateral control eyes inoculated with AAV-GFP. Compared with the normal optic nerve, it limited RGC loss to 9%.


CONCLUSIONS
Viral-mediated delivery of antioxidant genes provides long-lasting suppression against neuronal and axonal loss associated with permanent visual disability in patients with optic neuritis and multiple sclerosis.
Department of Ophthalmology, University of Florida, College of Medicine, Gainesville, FL 32610-0284, USA.
Xiaoping
X
Qi
Liang
L
Sun
Alfred S
AS
Lewin
William W
WW
Hauswirth
John
J
Guy
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001284:Atrophy; D001369:Axons / Q000473:pathology; D015153:Blotting, Western; D002374:Catalase / Q000235:genetics* / Q000378:metabolism; D002478:Cells, Cultured; D002908:Chronic Disease; D000229:Dependovirus / Q000235:genetics; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000201:enzymology / Q000473:pathology / Q000628:therapy; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology; D015316:Genetic Therapy; D005822:Genetic Vectors; D007267:Injections; D008279:Magnetic Resonance Imaging; D051379:Mice; D008811:Mice, Inbred DBA; D016253:Microscopy, Immunoelectron; D009103:Multiple Sclerosis / Q000201:enzymology / Q000473:pathology / Q000628:therapy; D009186:Myelin Sheath / Q000378:metabolism; D019636:Neurodegenerative Diseases / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D009900:Optic Nerve / Q000201:enzymology / Q000473:pathology; D009902:Optic Neuritis / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D051381:Rats; D012165:Retinal Ganglion Cells / Q000201:enzymology; D013482:Superoxide Dismutase / Q000235:genetics* / Q000378:metabolism
D000975:Antioxidants; D002374:Catalase; C441642:SOD3 protein, human; D013482:Superoxide Dismutase